Harmony Biosciences Holdings (HRMY) Asset Utilization Ratio (2020 - 2026)
Harmony Biosciences Holdings recorded quarterly Asset Utilization Ratio of 0.71 in Q1 2026, up 0.94% quarter-over-quarter from 0.7 in Q4 2025, and down 2.48% year-over-year from 0.73 in Q1 2025.
Harmony Biosciences Holdings' Asset Utilization Ratio history runs 7 years deep, the most recent figure standing at 0.71 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 2.48% year-over-year to 0.71; the TTM figure through Mar 2026 stood at 0.71 (down 2.48% YoY), while the FY2025 annual figure was 0.76, down 3.12% from the prior year.
- Asset Utilization Ratio came in at 0.71 for Q1 2026 at Harmony Biosciences Holdings, up from 0.7 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.77 in Q2 2024 to a low of 0.66 in Q4 2022.
- A 5-year average of 0.72 and a median of 0.71 in 2025 frame the typical range for Asset Utilization Ratio.
- On a YoY basis, Asset Utilization Ratio climbed as much as 41.28% in 2022 and fell as far as 10.27% in 2022.
- Harmony Biosciences Holdings' Asset Utilization Ratio stood at 0.66 in 2022, then increased by 10.19% to 0.73 in 2023, then increased by 1.26% to 0.74 in 2024, then declined by 5.56% to 0.7 in 2025, then rose by 0.94% to 0.71 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.71, 0.7, and 0.71 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 0.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.71 |
| Dec 31, 2025 | 0.70 |
| Sep 30, 2025 | 0.71 |
| Jun 30, 2025 | 0.71 |
| Mar 31, 2025 | 0.73 |
| Dec 31, 2024 | 0.74 |
| Sep 30, 2024 | 0.76 |
| Jun 30, 2024 | 0.77 |
| Mar 31, 2024 | 0.74 |
| Dec 31, 2023 | 0.73 |
| Sep 30, 2023 | 0.70 |
| Jun 30, 2023 | 0.68 |
| Mar 31, 2023 | 0.68 |
| Dec 31, 2022 | 0.66 |
| Sep 30, 2022 | 0.70 |
| Jun 30, 2022 | 0.75 |
| Mar 31, 2022 | 0.74 |
| Dec 31, 2021 | 0.74 |
| Sep 30, 2021 | 0.72 |
| Jun 30, 2021 | 0.68 |
| Mar 31, 2021 | 0.52 |
| Dec 31, 2020 | 0.43 |